These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38493314)

  • 1. Performance of the EORTC and CUETO Models to Predict Recurrence and Progression in High-risk Non-muscle-invasive Bladder Cancer Patients.
    Pazır Y; Esmeray A; Gelmis M; Caglar U; Ozgor F; Sarılar O; Akbulut F
    Urol J; 2024 May; 21(3):169-174. PubMed ID: 38493314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection.
    Zhang G; Steinbach D; Grimm MO; Horstmann M
    World J Urol; 2019 Dec; 37(12):2699-2705. PubMed ID: 30911812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder.
    Xylinas E; Kent M; Kluth L; Pycha A; Comploj E; Svatek RS; Lotan Y; Trinh QD; Karakiewicz PI; Holmang S; Scherr DS; Zerbib M; Vickers AJ; Shariat SF
    Br J Cancer; 2013 Sep; 109(6):1460-6. PubMed ID: 23982601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): A cohort analysis.
    Jobczyk M; Stawiski K; Fendler W; Różański W
    Cancer Med; 2020 Jun; 9(11):4014-4025. PubMed ID: 32216043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting recurrence and progression of non-muscle-invasive bladder cancer in Korean patients: a comparison of the EORTC and CUETO models.
    Choi SY; Ryu JH; Chang IH; Kim TH; Myung SC; Moon YT; Kim KD; Kim JW
    Korean J Urol; 2014 Oct; 55(10):643-9. PubMed ID: 25324946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting recurrence and progression in Chinese patients with nonmuscle-invasive bladder cancer using EORTC and CUETO scoring models.
    Xu T; Zhu Z; Zhang X; Wang X; Zhong S; Zhang M; Shen Z
    Urology; 2013 Aug; 82(2):387-93. PubMed ID: 23759377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comparison of EORTC And CUETO Risk Tables in Terms of the Prediction of Recurrence and Progression in All Non-Muscle-Invasive Bladder Cancer Patients.
    Dalkilic A; Bayar G; Kilinc MF
    Urol J; 2019 Feb; 16(1):37-43. PubMed ID: 30120763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
    Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
    Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer.
    Krajewski W; Aumatell J; Subiela JD; Nowak Ł; Tukiendorf A; Moschini M; Basile G; Poletajew S; Małkiewicz B; Del Giudice F; Maggi M; Chung BI; Cimadamore A; Galosi AB; Fave RFD; D'Andrea D; Shariat SF; Hornak J; Babjuk M; Chorbińska J; Teoh JY; Muilwijk T; Joniau S; Tafuri A; Antonelli A; Panunzio A; Alvarez-Maestro M; Simone G; Mastroianni R; Łaszkiewicz J; Lonati C; Zamboni S; Simeone C; Niedziela Ł; Candela L; Macek P; Contieri R; Hidalgo BG; Rivas JG; Sosnowski R; Mori K; Mir C; Soria F; González-Padilla DA; Faba ÒR; Palou J; Ploussard G; Rajwa P; Hałoń A; Laukhtina E; Pradere B; Tully K; Burgos FJ; Cidre MÁJ; Szydełko T;
    Urol Oncol; 2022 Nov; 40(11):491.e11-491.e19. PubMed ID: 35851185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in a United States Population.
    Ravvaz K; Walz ME; Weissert JA; Downs TM
    J Urol; 2017 Oct; 198(4):824-831. PubMed ID: 28433642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel.
    Soukup V; Čapoun O; Cohen D; Hernández V; Burger M; Compérat E; Gontero P; Lam T; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Yuan Y; Zigeuner R; Babjuk M
    Eur Urol Focus; 2020 May; 6(3):479-489. PubMed ID: 30470647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep Learning-based Recalibration of the CUETO and EORTC Prediction Tools for Recurrence and Progression of Non-muscle-invasive Bladder Cancer.
    Jobczyk M; Stawiski K; Kaszkowiak M; Rajwa P; Różański W; Soria F; Shariat SF; Fendler W
    Eur Urol Oncol; 2022 Feb; 5(1):109-112. PubMed ID: 34092528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with intravesical chemotherapy.
    Lammers RJ; Palou J; Witjes WP; Janzing-Pastors MH; Caris CT; Witjes JA
    BJU Int; 2014 Aug; 114(2):193-201. PubMed ID: 24304638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. External validation of European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment scoring models to predict recurrence and progression in Japanese patients with non-muscle invasive bladder cancer treated with bacillus Calmette-Guérin.
    Kohjimoto Y; Kusumoto H; Nishizawa S; Kikkawa K; Kodama Y; Ko M; Matsumura N; Hara I
    Int J Urol; 2014 Dec; 21(12):1201-7. PubMed ID: 25074295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk prediction scores for recurrence and progression of non-muscle invasive bladder cancer: an international validation in primary tumours.
    Vedder MM; Márquez M; de Bekker-Grob EW; Calle ML; Dyrskjøt L; Kogevinas M; Segersten U; Malmström PU; Algaba F; Beukers W; Ørntoft TF; Zwarthoff E; Real FX; Malats N; Steyerberg EW
    PLoS One; 2014; 9(6):e96849. PubMed ID: 24905984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer].
    Yang WX; Shao YX; Hu X; Xiong SC; Liu Y; Li X
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Mar; 52(2):326-333. PubMed ID: 33829710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups.
    Piao XM; Kim SK; Byun YJ; Zheng CM; Kang HW; Kim WT; Kim YJ; Lee SC; Kim WJ; Moon SK; Choi YH; Yun SJ
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factor assessment in high-risk, bacillus Calmette-Guérin-treated, non-muscle-invasive bladder cancer.
    Holz S; Albisinni S; Gilsoul J; Pirson M; Duthie V; Quackels T; Vanden Bossche M; Roumeguère T
    Res Rep Urol; 2017; 9():195-202. PubMed ID: 29034222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. External validation of the EORTC and NCCN bladder cancer recurrence and progression risk calculators in a U.S. community-based health system.
    Leo MC; McMullen CK; O'Keeffe-Rosetti M; Weinmann S; Garg T; Nielsen ME
    Urol Oncol; 2020 Feb; 38(2):39.e21-39.e27. PubMed ID: 31711836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.